Ruwini D. Rajapaksha
Ruwini D. Rajapaksha has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Mahinda I. Ranasinghe
Department of Chemistry, Wayne State University, Detroit, Michigan 48202, USA
6 shared publications - Cody J. Champion
Department of Biology, New Mexico State University, Las Cruces, NM, USA
2 shared publications John T. Farmer
Lovelace Biomedical Research Institute
2 shared publications- Liliya V. Frolova
Departments of Chemistry and Biology , New Mexico Institute of Mining and Technology , Socorro , New Mexico 87801 , United States
2 shared publications Snezna Rogelj
Department of Biology, New Mexico Institute of Mining and Technology, 801 Leroy Place, Socorro, New Mexico 87801, USA
2 shared publicationsAlexander Kornienko
Department of Chemistry, New Mexico Tech, 801 Leroy Place, Socorro, NM 87801, USA
1 shared publication
Latest Publications
- 11 February 2026
- Published by Taylor & Francis in Bioanalysis
- Vol. 18 (3) , 293-311
Regulatory and scientific considerations in PK and biomarker assay validation: lessons from bioanalytical practice
Bioanalytical method validation is a foundation of drug development, ensuring that pharmacokinetic (PK), toxicokinetic (TK), and biomarker assays produce accurate, precise, reliable, and decision-enabling data. Over the past several decades, advances in analytical technologies including ligand-binding assays (LBAs) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) platforms have transformed the field of bioanalysis. Regulatory guidance from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the International Council for Harmonization (ICH) has evolved to reflect these advancements. This review provides a comprehensive comparison of PK and biomarker assay validation, highlighting critical parameters such as selectivity, sensitivity, calibration, accuracy, precision, dilution/parallelism, specificity, and stability. Best practice recommendations are provided for method development, qualification, and validation, with a focus on fit-for-purpose (FFP) approaches and context-of-use (CoU) considerations. Areas of ambiguity in current regulatory expectations for biomarker validations, common pitfalls encountered during regulatory interactions, and emerging trends in bioanalysis are also reviewed. This review paper aims to guide bioanalytical scientists in developing robust, compliant assays that support regulatory submissions and facilitate informed drug development decisions.
- 11 February 2026
- Published by Taylor & Francis in Bioanalysis
- Vol. 18 (3) , 293-311
Regulatory and scientific considerations in PK and biomarker assay validation: lessons from bioanalytical practice
Bioanalytical method validation is a foundation of drug development, ensuring that pharmacokinetic (PK), toxicokinetic (TK), and biomarker assays produce accurate, precise, reliable, and decision-enabling data. Over the past several decades, advances in analytical technologies including ligand-binding assays (LBAs) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) platforms have transformed the field of bioanalysis. Regulatory guidance from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the International Council for Harmonization (ICH) has evolved to reflect these advancements. This review provides a comprehensive comparison of PK and biomarker assay validation, highlighting critical parameters such as selectivity, sensitivity, calibration, accuracy, precision, dilution/parallelism, specificity, and stability. Best practice recommendations are provided for method development, qualification, and validation, with a focus on fit-for-purpose (FFP) approaches and context-of-use (CoU) considerations. Areas of ambiguity in current regulatory expectations for biomarker validations, common pitfalls encountered during regulatory interactions, and emerging trends in bioanalysis are also reviewed. This review paper aims to guide bioanalytical scientists in developing robust, compliant assays that support regulatory submissions and facilitate informed drug development decisions.
- 2 January 2026
- Published by Taylor & Francis in Bioanalysis
- Vol. 18 (1) , 91-109
Progress and promise of pharmacodynamic biomarkers: novel strategies and assay considerations in drug development
Pharmacodynamic (PD) biomarkers provide crucial insights into a drug's mechanism of action (MoA) and efficacy by measuring its effects on biological targets within an organism. PD biomarkers can be proximal (e.g. receptor occupancy, enzyme inhibition) or distal (e.g. downstream pathway modulation) to the biological target. In drug development, PD biomarkers are essential for monitoring patient response, assessing therapeutic efficacy, optimizing dosage strategies, and streamlining the drug development process by informing go/no-go decisions. In personalized medicine, PD biomarkers enable tailored treatments based on individual responses, enhancing both effectiveness and safety. Sound bioanalytical strategies and rigorous assay validation practices are key for successful integration of PD biomarkers into clinical trials. This paper outlines the bioanalytical and assay considerations for developing and validating informative PD biomarker assays and their use in drug development.
- 2 January 2026
- Published by Taylor & Francis in Bioanalysis
- Vol. 18 (1) , 91-109
Progress and promise of pharmacodynamic biomarkers: novel strategies and assay considerations in drug development
Pharmacodynamic (PD) biomarkers provide crucial insights into a drug's mechanism of action (MoA) and efficacy by measuring its effects on biological targets within an organism. PD biomarkers can be proximal (e.g. receptor occupancy, enzyme inhibition) or distal (e.g. downstream pathway modulation) to the biological target. In drug development, PD biomarkers are essential for monitoring patient response, assessing therapeutic efficacy, optimizing dosage strategies, and streamlining the drug development process by informing go/no-go decisions. In personalized medicine, PD biomarkers enable tailored treatments based on individual responses, enhancing both effectiveness and safety. Sound bioanalytical strategies and rigorous assay validation practices are key for successful integration of PD biomarkers into clinical trials. This paper outlines the bioanalytical and assay considerations for developing and validating informative PD biomarker assays and their use in drug development.
- 3 July 2025
- Published by Taylor & Francis in Bioanalysis
- Vol. 17 (13) , 871-880
Evaluation of singlicate vs duplicate analysis in ligand binding assays: a case study with IFN-γ in mouse and NHP models
The use of duplicate analysis in biomarker assays is a standard practice. While it does not inherently increase variability or contribute to assay failure, it can reveal the high variability associated with manual pipetting, thereby highlighting potential issues within the assy. This study evaluated the reliability of singlicate analysis compared to duplicate analysis for interferon-gamma (IFN-γ) assays using ELISA in mouse and non-human primate (NHP) serum samples. Assay performance was assessed across 50 plates, with results analyzed for minimum required dilution (MRD), standard curve linearity, surrogate sample accuracy, recovery, precision, and variability between analysts, including both an experienced and a novice analyst. There were minimal differences in relative accuracy, and precision between singlicate and duplicate analysis, with CVs less than 5% for both methods. Singlicate and duplicate-generated standard curves were strongly correlated (NHP R2 = 0.9995, mouse R2 = 1.0000). Analyst variability had less impact on singlicate analysis, with lower inter-analyst CVs (1.0-6.5%) compared to duplicate analysis (5.0-7.5%). These findings underscore the robustness of singlicate analysis. A workflow for singlicate assay validation is proposed, demonstrating its potential to streamline biomarker assay development while ensuring regulatory compliance. This study supports the adoption of singlicate analysis as a viable alternative to conventional duplicate methods for biomarker assays.
- 3 July 2025
- Published by Taylor & Francis in Bioanalysis
- Vol. 17 (13) , 871-880
Evaluation of singlicate vs duplicate analysis in ligand binding assays: a case study with IFN-γ in mouse and NHP models
The use of duplicate analysis in biomarker assays is a standard practice. While it does not inherently increase variability or contribute to assay failure, it can reveal the high variability associated with manual pipetting, thereby highlighting potential issues within the assy. This study evaluated the reliability of singlicate analysis compared to duplicate analysis for interferon-gamma (IFN-γ) assays using ELISA in mouse and non-human primate (NHP) serum samples. Assay performance was assessed across 50 plates, with results analyzed for minimum required dilution (MRD), standard curve linearity, surrogate sample accuracy, recovery, precision, and variability between analysts, including both an experienced and a novice analyst. There were minimal differences in relative accuracy, and precision between singlicate and duplicate analysis, with CVs less than 5% for both methods. Singlicate and duplicate-generated standard curves were strongly correlated (NHP R2 = 0.9995, mouse R2 = 1.0000). Analyst variability had less impact on singlicate analysis, with lower inter-analyst CVs (1.0-6.5%) compared to duplicate analysis (5.0-7.5%). These findings underscore the robustness of singlicate analysis. A workflow for singlicate assay validation is proposed, demonstrating its potential to streamline biomarker assay development while ensuring regulatory compliance. This study supports the adoption of singlicate analysis as a viable alternative to conventional duplicate methods for biomarker assays.
- 21 May 2021
- Published by American Chemical Society (ACS) in Environmental Science & Technology
- Vol. 55 (12) , 8090-8096
A Rapid and Sensitive Chemical Screening Method for E-Cigarette Aerosols Based on Runtime Cavity Ringdown Spectroscopy
Growing demand of Juul and other electronic cigarettes, despite critical knowledge gaps about their chemical composition, has led to concerns regarding their potential health effects. We introduce a novel analytical approach, runtime cavity ringdown spectroscopy (rtCRDS) for rapid detection of oxidative products in e-cigarette aerosols, to facilitate the study of aerosol from a single puff of e-liquid. We report a systematic investigation of three flavors of commercial Juul pods (Virginia tobacco, mango, and menthol) and known commercial e-liquid ingredients (propylene glycol (PG), vegetable glycerin (VG), nicotine, ethyl maltol, benzoic acid, and nicotine benzoate) vaped using Juul devices. Juul e-liquids and neat chemical additives spiked into a 30:70 PG/VG solution were vaped and their aerosols were collected in 1-L Tedlar gas bags and analyzed using rtCRDS. Acetaldehyde, formaldehyde, and acetone were identified as primary oxidative products in aerosolized PG/VG. Ethanol was detected as a major constituent of the three commercial Juul flavors. Spectral intensities of carbonyl compounds increased with the addition of spikes, benzoic acid, ethyl maltol, and nicotine to PG/VG, suggesting that oxidative product generation increases with common additives. The method of direct, rapid analysis of e-cig aerosols introduced here can be used to complement traditional methods in vaping exposures.
- 21 May 2021
- Published by American Chemical Society (ACS) in Environmental Science & Technology
- Vol. 55 (12) , 8090-8096
A Rapid and Sensitive Chemical Screening Method for E-Cigarette Aerosols Based on Runtime Cavity Ringdown Spectroscopy
Growing demand of Juul and other electronic cigarettes, despite critical knowledge gaps about their chemical composition, has led to concerns regarding their potential health effects. We introduce a novel analytical approach, runtime cavity ringdown spectroscopy (rtCRDS) for rapid detection of oxidative products in e-cigarette aerosols, to facilitate the study of aerosol from a single puff of e-liquid. We report a systematic investigation of three flavors of commercial Juul pods (Virginia tobacco, mango, and menthol) and known commercial e-liquid ingredients (propylene glycol (PG), vegetable glycerin (VG), nicotine, ethyl maltol, benzoic acid, and nicotine benzoate) vaped using Juul devices. Juul e-liquids and neat chemical additives spiked into a 30:70 PG/VG solution were vaped and their aerosols were collected in 1-L Tedlar gas bags and analyzed using rtCRDS. Acetaldehyde, formaldehyde, and acetone were identified as primary oxidative products in aerosolized PG/VG. Ethanol was detected as a major constituent of the three commercial Juul flavors. Spectral intensities of carbonyl compounds increased with the addition of spikes, benzoic acid, ethyl maltol, and nicotine to PG/VG, suggesting that oxidative product generation increases with common additives. The method of direct, rapid analysis of e-cig aerosols introduced here can be used to complement traditional methods in vaping exposures.
- 1 July 2020
- Published by Elsevier in Journal of Environmental Sciences
- Vol. 93, 30-40
Peroxymonosulfate decomposition by homogeneous and heterogeneous Co: Kinetics and application for the degradation of acetaminophen
- 1 July 2020
- Published by Elsevier in Journal of Environmental Sciences
- Vol. 93, 30-40
Peroxymonosulfate decomposition by homogeneous and heterogeneous Co: Kinetics and application for the degradation of acetaminophen
- 1 September 2019
- Published by Elsevier in Solar Energy
- Vol. 189, 503-509
Colloidal CuZnInS3 nanocrystals as the sensitizer in photovoltaic solar cells
- 1 September 2019
- Published by Elsevier in Solar Energy
- Vol. 189, 503-509
Colloidal CuZnInS3 nanocrystals as the sensitizer in photovoltaic solar cells
- 6 March 2019
- Published by Elsevier in Journal of Photochemistry and Photobiology A: Chemistry
- Vol. 376, 73-79
Photo-physical properties of substituted 2,3-distyryl indoles: Spectroscopic, computational and biological insights
- 6 March 2019
- Published by Elsevier in Journal of Photochemistry and Photobiology A: Chemistry
- Vol. 376, 73-79
Photo-physical properties of substituted 2,3-distyryl indoles: Spectroscopic, computational and biological insights
- 1 January 2019
- Published by Springer Nature in MRS Advances
- Vol. 4 (16) , 953-958
Quantum Dots as Photocatalysts for Bicarbonate Reduction to Solar Fuels: Formate Production from CuS, CuInS2, and CuInS2/ZnS
- 1 January 2019
- Published by Springer Nature in MRS Advances
- Vol. 4 (16) , 953-958
Quantum Dots as Photocatalysts for Bicarbonate Reduction to Solar Fuels: Formate Production from CuS, CuInS2, and CuInS2/ZnS
- 1 June 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 28 (10) , 1879-1886
Photoactivated 2,3-distyrylindoles kill multi-drug resistant bacteria
- 1 June 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 28 (10) , 1879-1886
Photoactivated 2,3-distyrylindoles kill multi-drug resistant bacteria
- 5 January 2018
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry A
- Vol. 122 (4) , 937-945
Spectroscopic Study of a Photoactive Antibacterial Agent: 2,3-Distyrylindole
Optical properties and fluorescence decay dynamics of a photoactive indole based antibacterial chromophore system, 2,3-distyrylindole (23DSI), were investigated using various spectroscopic characterization techniques. Experimental studies were done by utilizing steady-state UV–vis spectroscopy, steady-state fluorescence spectroscopy, time-resolved fluorescence upconversion spectroscopy, and time-correlated single-photon counting spectroscopy. Our studies show that the 23DSI molecule has a multiphoton absorption property as indicated by two- and three-photon absorption in the both the solution and the solid phases. The ultrafast time-resolved fluorescence upconversion studies show that this molecule undergoes a fast decay process with an average time constant of 34 ps, a single exponential decay, and an average fluorescence lifetime of 1 ns. The compound 23DSI did not show any signs of singlet oxygen production. The density functional theory (DFT) calculations showed that the 23DSI molecule has conjugated electron densities that are responsible for multiphoton absorption. The chlorine-substituted styryl groups, attached to the central indole ring facilitate the excellent electron delocalization within the molecule. This optimal electron delocalization, combined with the good electron conjugation in the 23DSI molecule is important for efficient multiphoton absorption and is in excellent agreement with experimental observations. Both the optical spectrum and emission spectrum using DFT calculations are also surprisingly well matched with the experimentally measured UV–vis spectrum and the emission spectrum, respectively. Combined experimental and theoretical studies suggest that excited electrons initially relax to the singlet state (S1) by internal conversion (IC) and subsequently relax back to their ground state by emitting absorbed energy as fluorescence emission. The outstanding multiphoton absorption capabilities of this 23DSI molecule support its potential application in both biological imaging and photodynamic inactivation (PDI).
- 5 January 2018
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry A
- Vol. 122 (4) , 937-945
Spectroscopic Study of a Photoactive Antibacterial Agent: 2,3-Distyrylindole
Optical properties and fluorescence decay dynamics of a photoactive indole based antibacterial chromophore system, 2,3-distyrylindole (23DSI), were investigated using various spectroscopic characterization techniques. Experimental studies were done by utilizing steady-state UV–vis spectroscopy, steady-state fluorescence spectroscopy, time-resolved fluorescence upconversion spectroscopy, and time-correlated single-photon counting spectroscopy. Our studies show that the 23DSI molecule has a multiphoton absorption property as indicated by two- and three-photon absorption in the both the solution and the solid phases. The ultrafast time-resolved fluorescence upconversion studies show that this molecule undergoes a fast decay process with an average time constant of 34 ps, a single exponential decay, and an average fluorescence lifetime of 1 ns. The compound 23DSI did not show any signs of singlet oxygen production. The density functional theory (DFT) calculations showed that the 23DSI molecule has conjugated electron densities that are responsible for multiphoton absorption. The chlorine-substituted styryl groups, attached to the central indole ring facilitate the excellent electron delocalization within the molecule. This optimal electron delocalization, combined with the good electron conjugation in the 23DSI molecule is important for efficient multiphoton absorption and is in excellent agreement with experimental observations. Both the optical spectrum and emission spectrum using DFT calculations are also surprisingly well matched with the experimentally measured UV–vis spectrum and the emission spectrum, respectively. Combined experimental and theoretical studies suggest that excited electrons initially relax to the singlet state (S1) by internal conversion (IC) and subsequently relax back to their ground state by emitting absorbed energy as fluorescence emission. The outstanding multiphoton absorption capabilities of this 23DSI molecule support its potential application in both biological imaging and photodynamic inactivation (PDI).